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Abstract 
 
Background: Depression has been consistently linked with inflammation. For that reason, 
several anti-inflammatory strategies are currently under scrutiny for depression treatment and 
prevention. Statins have anti-inflammatory and antioxidant properties. Most studies regarding 
statin effects in depression were conducted in younger populations, leaving a gap in the 
literature of their relationship with late-life depression. In this study, we aimed to investigate 
the association of statin intake and depression prevalence in community dwelling older adults 
living in Australia and the United States. 
 
Methods: We analysed baseline data from a large randomized double-blind placebo controlled 
trial examining the efficacy of low-dose aspirin on extending dementia-free and physical 
disability-free life in a healthy elderly population, known as ASPREE (ASPirin in Reducing 
Events in the Elderly). ASPREE recruited 19,114 participants, over 70 years of age (over 65 
years, if from ethnic minority background). The association of self-reported statin use and 
depression prevalence, as measured by a validated depression scale (CES-D 10), was 
determined using logistic regression models. Multivariable logistic models were implemented 
to account for important demographics and other lifestyle and socio-economic factors, such as 
gender, education, smoking, and living status. 
 
Results: A total of 5,987 individuals were statin users at baseline. Of those, 633 (10.658%) 
presented with depressive symptoms (CES-D cut-off >8), against 1,246 (9.549%) in the non-
statin users. In the unadjusted model, statin use was associated with an increase in depression 
prevalence (OR: 1.13; CI: 1.02 – 1.25, p= 0.02). However, after adjusting for important 
Formatted: Line spacing:  Double
Commented [MN1]: Avoid over precision especially with 
percentages which ideally should be whole numbers. 
demographic and socioeconomic factors, the use of statins was not significantly associated with 
depression (OR: 1.09; CI 0.98 – 1.20, p=0.11). In a secondary analysis of each statin brand 
individually, only Simvastatin was significantly associated with a 16% increased odds of 
depression in this population (OR: 1.16, CI 0.99-1.35, p=0.05). Sub-group analysis showed a 
protective effect of statins in individuals with a BMI > 35 (OR: 0.69, CI 0.51 – 0.95, p=0.02) 
  
Conclusion: This study in a large sample of community dwelling older population fails to 
confirmdid not show any association of statins and late life depression, after accounting for 
important socioeconomic and demographic factors in a large sample of community dwelling 
older population. In secondary analyses, only simvastatin was associated with increased 
prevalence of depressive symptoms. Statins showed a negative association with depression in 
individuals with severe obesity (BMI >35). 
 
Keywords: depression, late-life depression, statins, anti-inflammatory, treatment, prevention, 
metabolic syndrome.  
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 Introduction 
 
DLate-life depression is a common neuropsychiatric disorder that significantly 
diminishes quality of life in the elderly 1. Older people with depressive symptoms tend to have 
a poorer clinical course and prognosis of depressive symptomatology, with more refractory 
symptoms, less fewer changes in depression severity and longer time to remission, when 
compared to younger populations2. These distinct courses of disease may reflect different 
aetiologies and brain alterations when comparing late-life depression with depression at 
younger ages. However, treatment in older patients is generally approached in the same way 
as in younger patients 3. 
Depression has been consistently linked with inflammatory alterations at least in a 
subset of individuals 4 and late-life depression is not different 5. An interesting hypothesis states 
that older people tend to develop a pro-inflammatory status, characterized by high levels of 
pro-inflammatory markers in cells and tissues, a condition referred to as ‘“inflammageing’”. 
This is the result of several processes still under investigation, but ‘inflammageing’ has been 
pointed out as one of the possible mechanisms for the high vulnerability of older people to 
develop conditions often linked with inflammatory alterations 6. For that this reason, many 
anti-inflammatory strategies are currently under investigation for their potential therapeutic 
effects in the elderly 7. One of these studies, based on the premise of anti-inflammatory 
strategies for maintaining quality of life in an older population, is the ASPirin for the Reduction 
of Events in the Elderly (ASPREE). Its primary aim wass to investigate the impact of low-dose 
aAspirin on on inflammatory markers and its potential to extend dementia-free and physical 
disability-free time survival in a healthy elderly population8. ASPREE design and multiple 
endpoints are described in detail elsewhere8. In this study, part of the an ASPREE sub study 
(ASPREE-D) ASPREE-D, in which the endpoint is depression 7, we use baseline data of this 
large population to investigate the association of other drugs with anti-inflammatory properties 
and their relationship with depression, namely specifically Sstatins. 
Statins have anti-inflammatory and antioxidant properties, making it them one of thesea 
potential protective agent for depressions. Statins are one of the most prescribed drugs 
worldwide, with confirmed benefits in morbidity and mortality in patients with established 
cardiovascular diseases (CVD) 8,9, but with ongoing debate about their role in primary 
prevention in the elderly 10–12. While these drugs tend to be more widely prescribed, it is 
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important to understand their potential impact on mental health and quality of life in a 
progressively ageing populations 13. 
The relation between statin use and depression has been under investigation for a long 
time, with conflicting findings. While some studies found that statin use protects against 
depressive symptoms14–16 , others found that these medications might in fact increase this risk 
17–20, while others found no relationship at all 21. Interestingly, most of the studies that found a 
protective effect of statins in depression were conducted in younger populations and very few 
addressed statins role in late life depression, leaving this gap in medical knowledge to be 
addressed. 
Thus, using the ASPREE clinical trial baseline data22, comprising a large population of 
older adults, without established CVD, living in the community, we aim to examine the 
association of statin use and prevalence of depressive symptoms in this healthy elderly 
population.  
 
Methods 
 
Participants: This cross-sectional study is a sub-study of ASPREE, a large population-
based randomised controlled trial. We aim to investigate the association of statin use and 
depressive symptoms among healthy community dwelling older adults. For this purpose we 
analysed baseline data from a large randomized double-blind placebo controlled trial 
examining the efficacy of low-dose aspirin on extending dementia-free and physical disability-
free life in a healthy elderly population, ASPREE22. ASPREE has recruited 19,114 participants, 
over 70 years of age (>65 years if from minority background) from Australia and the United 
States. ASPREE recruitment strategy and instruments are described in detail elsewhere 23. 
 
Inclusion criteria: Community dwelling men and women 70 years of age and older (US 
minority 65 years of age and older) and willing and able to provide informed consent were 
study inclusion criteria.  
Exclusion criteria: Exclusion criteria included a past history of cardiovascular event or 
established cardiovascular disease or atrial fibrillation, dementia or a score of <78 on Modified 
Mini- Mental State examination, disability as defined by severe difficulty or inability to 
perform any one of the Katz activities of daily living, a condition with a high current or 
recurrent risk of bleeding, anaemia, a condition likely to cause death within 5 years, current 
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use of other antiplatelet or antithrombotic medication, current use of aspirin for secondary 
prevention, and uncontrolled hypertension. 
Instruments: Once enrolled in the study, subjects underwent a comprehensive 
assessment with multiple physical and mental health measures, providing a rich database 23. 
They answered a sociodemographic questionnaire that included age, education, gender, 
smoking status, alcohol use, living status and self-reported presence and history of a myriad of 
medical conditions, including depression, hypertension and diabetes. They also had their 
height, weight (used to calculate BMI) and abdominal circumference measured, along with 
blood pressure and heart rate. Blood samples were collected for laboratory measures, including 
lipid profile, glucose, creatinine and haemoglobin levels.  
 
Medication use: Number and type of concomitant medication use was also included in 
the questionnaire and coded according to the Anatomical Therapeutic Chemical Classification 
System of the World Health Organization. This was the information utilized in this study as 
indicative of statin use and number of concomitant medications. 
 
The Centre for Epidemiological Studies Depression (CES-D 10) Scale: The CES-D 10 
scale was used to quantify the presence of depressive symptoms 24. The CES-D 10 is a self-
completed questionnaire that scores the severity of depressive symptoms in general 
populations. Participants responded to each item of the scale by rating the frequency of each 
mood symptom “during the past week” on a four-point scale. All items are then summed up 
and provide a score that ranges from 0 to 30 25. This instrument has previously shown 
comparable accuracy to the full version of the CES-D (kappa = 0.97) in classifying participants 
with depressive symptoms 24. Specifically, in the context of depression in the elderly, construct 
validity of the CES-D 10 showed that a single score was a reliable and valid measure of 
depression in this population 26. In this study we used a cut-off of > 8 for definition of 
depression, a score validated previously in the elderly 26. 
 
Ethics: The ASPREE trial was conducted in accordance with the Declaration of 
Helsinki 1964 as revised in 2008, the NHMRC Guidelines on Human Experimentation, the 
federal patient privacy (HIPAA) law and ICH-GCP guidelines and the International 
Conference of Harmonisation Guidelines for Good Clinical Practice. ASPREE also follows the 
Code of Federal Regulations as it relates to areas of clinical research. 
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 Data quality and Governance: The study benefits from high-quality data as this is a sub-
study of a randomised control trial. The ASPREE Steering Committee is responsible for data 
management and access23.  All data were collected according to the same measurement 
protocol, with very small percentages of missing data (0.02%), resulting in a reliable and high-
quality dataset.  
  
Statistical analysis: Baseline sample characteristics of statin users and non-users were 
compared using independent sample t-tests for continuous measures or chi-square tests for 
categorical measures. The association of statin use with dichotomised depressive symptoms 
was determined using logistic regression models and odds ratios (ORs) and 95% confidence 
intervals (CIs) were reported. Multivariable logistic models were implemented to account for 
important demographics and other lifestyle and socio-economic factors, such as gender, 
education, smoking, and living status. Sub-group analysis was performed to account for 
Metabolic Syndrome factors individually. In order to avoid multicollinearity, stratified 
analyses were performed for age (<=74, 75-84, 85+), BMI (<=25, 25-30,30-35, 35+), presence 
of diabetes and high blood pressure and abdominal circumference (>88 cm in females, >102 
cm in males) 27. Sub-group analysis according to antidepressant use was also included. All 
statistical tests were two-tailed and p-value of <0.05 was considered to indicate statistical 
significance. All analyses were performed using STATA software, version 15.0. 
 
Results 
 
Table 1 shows characteristics of participants according to statin use status at trial entry 
(Table 1). Of 19,114 participants, 16,703 (87.4%) were from Australia and 2,411 (12.6%) from 
the USA. Mean age was 75, and the oldest participant was 98 years. Of those, 10,783 (56.4%) 
were female. 12,779 (66.9%) participants lived in a private home with family, friends or 
spouse, 18,263 (95.6%) were of English speaking background, and 4,276 (22.4%) were born 
overseas. Of 1,664 ethical minority participants, 1,323 (80%) were from the United States. 
Current smoking was reported by 735 (3.9%) and 14,642 (76.6%) were current alcohol 
consumers.  
Overall 1,879 (9.8%) had a CES-D 10 score of >8. Depression was more prevalent in 
females (n = 1,248; 11.6%) when compared to males (n = 631; 7.6%). Depression was also 
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(11.22%). Of those, 456 (21.27%) remained depressed according to our cut-off, while 1,688 
(78.73) were found to be in remission or were taking antidepressants for another reason, other 
than depression. 
Blood lipid profile was significantly different among groups, with statin users 
presenting having lower levels of total cholesterol, LDL and HDL, and higher levels of 
triglycerides. Statin users also had higher presence of diabetes, high blood pressure and 
elevated abdominal circumference. They also tend to use more concomitant medications 
compared to non-statin users (Table 1).  
 Statin use was self-reported in 5,987 individuals (31% of total participants). 
Atorvastatin was the most frequently used statin (n=2,268), followed by Simvastatin (n=1,777), 
Rosuvastatin (n=1,527), Pravastatin (n=348), Lovastatin (n=55), Fluvastatin (n=16) and 
Pitavastatin (n=1). After logistic regression of each specific statin brand individually, only 
Simvastatin was statistically significantly associated with depressive symptoms (Table 2). All 
other prevalent statin brands were not significant at 0.05 level: Atorvastatin (OR: 0.99; 95% 
CI 0.86-1.15, p=0.95), Lovastatin (OR: 1.12; CI 0.48-2.62, p=0.78), Pravastatin (OR: 1.06; CI 
0.75-1.5, p= 0.75), Rosuvastatin (OR: 1.11; CI: 0.94-1.32, p=0.21).  
The crude and adjusted analyses for examining the association between statin and 
simvastatin use and depression (defined by CES-D score of >= 8) are summarized in table 2. 
In the crude analysis, both statin use and Simvastatin use were significantly associated with 
increased risk for depression. However, after adjusting for important demographics and SES 
factors, (i.e. gender, age, living status, education and smoking history), statins were no longer 
significantly associated with increased depression risk (OR: 1.09; CI: 0.98 – 1.20, p=0.11). Of 
the individual statins after adjustment, only Simvastatin remained significantly associated with 
a 16% increased risk of depressive symptoms in this population (p<0.05).  
 
Subgroup analysis are shown in table 3. Association between statin use and depression 
was significant in 75-84 years sub-group analysis. There was a 21% increase in depression 
prevalence among statin users after accounting for important demographics and SES factors. 
There was also a significant association in BMI 25-30, and over 35 sub-group analysess. There 
was a 16% increase in depression prevalence in statin users in BMI 25-30 sub-group. In 
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contrary, individuals taking statins and with a BMI over 35 (severe obesity) showed a 31% 
decreased in depression prevalence compared to non-statin users. There were no significant 
differences according to antidepressant use. No other subgroups were statistically significantly 
associated with depression.   
 
Discussion 
 
The primary outcome,After fully adjustinged for confounders we results of this large 
study in a healthy community dwelling older population failed to showfound that statin use 
was not associated with an altered prevalence of depression in a healthy community dwelling 
older population. However, before accounting for major demographic, socioeconomic and 
clinical characteristics, there was a significant association between statin use and depressive 
symptoms. Simvastatin use, after adjustment was associated with an increased risk of 
depression. This study thus fails to confirm a protective effect of statins in late life depression.  
The relation between statin use and depression has been under investigation for a long 
time, with  conflicting findings 18,28,29. Heterogeneity (De.g. different study designs, different 
instruments for measuring depression and mainly distinct study populations) make it difficult 
to analyse results in large meta-analyseis. The majority of studies that found any benefits of 
statins on psychological wellbeing were conducted in younger populations or without any age 
restrictions 14–16,30. Studies conducted specifically in older populations are still scarce.  
One similar observational study conducted in this specific age group, showed that in a 
population of 329 subjects aged >= 65 years, living in their own home, in Italy, statin use was 
associated with increased rate of depressive symptoms (measured by the Geriatric Depression 
Scale) and cognitive decline, after controlling for important confounding factors, such as 
demographic and socioeconomic status, smoking and the presence of clinical conditions, such 
as dyslipidaemia, diabetes and  hypertension (OR: 1.70; CI: 0.98 – 2.96, p= 0.02) 17. There 
were no significant differences between individual statin brands in this analysis17. 
The only longitudinal study conducted in the elderly investigating this association was 
performed as part of the Singaporean Longitudinal Ageing Studies cohort in 2009. In this study 
of 1803 individuals living in the community, the authors found no association between statin 
use and depressive symptoms (as measured by the Geriatric Depression Scale) after 1.5 years 
of follow up, in their adjusted analysis (ß = - 0.12, p = 0.23). Post hoc findings suggested a 
protective effect of statins in women (ß = - 0.29, p= 0.02) and association with more depressive 
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symptoms in men, particularly those with medical comorbidities (ß = 0.63, p=0.04) and 
multiple drug use (ß = 0.74, p=0.02) 31.  
One possible explanation for our findings could be participants’ characteristics.  Table 
1 shows that statin users tend to include more females and are generally less educated than the 
non-statin users, factors associated with higher depression occurence31. They also differ in 
important physical characteristics. They have higher BMI’s and abdominal circumferences 
(direct measures of obesity) as well as higher rates of diabetes and hypertension (Table 1). 
Each of these conditions have been previously linked to increased risk of late life depression 
32–34 . These factors tend to coalesce to for the metabolic syndrome (MS). MS criteria includes 
elevated blood pressure, abdominal obesity, dyslipidaemia and increased blood sugar 27. MS 
constitutes an important risk factor for the development of many somatic conditions, including 
cardiovascular disease (CVD), diabetes, cognitive impairment and even cancer, constituting 
one potential link between depression and somatic disorders 35. A recent review suggests that 
abdominal obesity and lipid disturbances are the driving force behind the relationship between 
depression and MS 32. Once both are present, abdominal obesity gives rise to multiple 
immunometabolic dysregulations, often related to incidence or persistence of depression 27. 
White adipose tissue, especially in the abdominal area, is an active endocrine organ producing 
inflammatory cytokines and hormones that disrupt inflammatory pathways 36. The metabolic 
syndrome is consistently linked to depression, hypothetically through persistent low-grade 
inflammation 32,37. Increased inflammatory activity also disrupts HPA axis regulation, one of 
the most consistent biological findings in patients with depression 38. The presence of MS has 
been associated with symptom severity and chronicity in late life depression, as well as poorer 
antidepressant response 39. After these factors were taken into consideration in our study 
through sub-group analyses, the increased prevalence of depression in statin users was no 
longer statistically significant. Because MS includes lipid disorders, in which the mainstream 
of treatment are statins, statin intake might be considered as a marker of MS presence and not 
necessarily correlated with depression itself. This is also true for other conditions and 
medications linked with possible neuropsychiatric adverse events 40.  
Another possible explanation is that late life depression differs substantially from 
depression in other age groups regarding aetiology and prognosis 2. Late life depression  has 
been showend to be more associated with vascular damage and morphologic alterations of 
brain structures 41,42. It may be that in younger age groups, before brain change has occurred, 
a greater benefit from anti-inflammatory strategies may arise. Once brain change has happened, 
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anti-inflammatory drugs may be unable to reverse the process, although they might still play a 
role in preventing it at early stages. 
On subgroup analysis, we found that participants with BMI over 35 were the only group 
in which statins appear to be a protective factor against depression, with a 30% reduction in 
depression prevalence in this group. This agrees with the inflammatory hypothesis, meaning 
that this is the group of patients with potentially higher inflammation levels, in which the anti- 
inflammatory and antioxidant properties of statins may exert its biggest influence. 
Unfortunately, we did not have access to inflammatory measures at this time, but evidence 
suggests that anti-inflammatory drugs tend to have a stronger antidepressant effect in patients 
with high inflammatory markers at baseline 43,44.  
In post-hoc analysis, we found that Simvastatin was associated with increased 
prevalence of depressive symptoms. Our findings agree with a large recent study of almost 
300,000 people initiating statin use in the USA20. This study aimed to compare the risk of 
lipophilic versus hydrophilic statins. The authors found that only Simvastatin was associated 
with an increased risk of depressive symptoms, although the effect size was not big 20. Several 
possible mechanisms have been suggested for the association of Simvastatin and depression. 
Simvastatin is the most lipophilic statin of all. Accordingly, it can more easily pass through the 
blood-brain barrier and directly influence mood 45. Brain cholesterol is synthesized by the brain 
itself, with little influence from external cholesterol, and rates of brain cholesterol synthesis 
tend to decrease with age 45. This high permeability might grant Simvastatin an increased 
potential to interfere in this delicate homeostasis, lowering brain cholesterol levels and 
interfering with myelination processes and the development of subsequent cognitive and mood 
symptoms 18. Consistently, lipophilic statins have been associated with suicidal ideation 46 and 
depressive symptoms in elderly populations 29.  Simvastatin is also the least hepatoselective of 
statins, making it more frequently associated with side effects, which may diminish quality of 
life, predisposing to mood symptoms 47. It is also possible that suppression of peripheral 
inflammatory markers is a mechanism whereby statins may be active. Data from the JUPITER 
study shows that Rosuvastatin reduces such markers 48, although the relative contribution of 
suppression of peripheral compared to central inflammation as a mechanism of action remains 
to be clarified.  
Strengths of this study include a much larger sample of older adults, a comprehensive 
assessment of individuals, validated instruments for depression measurement and robust data 
on mental and physical conditions, which gives us a high-resolution lens to explore this 
relationship in an elderly population. Accounting for a variety of socio-economic factors and 
physical conditions, especially those related to metabolic syndrome, in well powered 
multivariable models was another advantage. ASPREE is a large and recent data bank 
regarding a healthy older age population 22. Also, the high-quality methodology in 
questionnaire administration 23, a depression scale validated in older people 26 and multiple 
physical measures, as well as laboratory measures, make it a valuable tool to investigate several 
associations in this specific population.  
 
There are several limitations in this study. First, due to its design, as a cross-sectional 
study, only association, and not causation, can be inferred by it. Longitudinal measures in the 
ASPREE cohort are not available yet to evaluate causal pathways, however this baseline study 
can be considered as an exploratory hypothesis generating ground for a confirmatory analysis 
based on the ASPREE cohort. Also, notwithstanding the fact that the CES-D 10 is a valuable 
tool for depression screening, it is not a formal diagnostic test for depression. Another 
limitation comes from exclusion criteria. Since ASPREE is a study of a healthy elderly 
population, excluding severe diseases, dementia, uncontrolled hypertension, and especially, 
people with a history of cardiovascular disease, these sub-groups were unable to be addressed 
in this investigation. CVD has been consistently linked to inflammation and depression 33,49 
and the effects of statins in reducing mortality in this population have been strongly 
documented in the literature 9,12. In theseis specific populations, statins may have more 
psychological benefits than in the individuals investigated in this study.  
 
This study provides evidence from a large and very well characterised sample of 
community dwelling older people on the controversial topic of statins for primary prevention 
of depression in the elderly. In conclusion, we found no effect of statins on depressive 
symptoms in a healthy community dwelling elderly population, after accounting for important 
confounding factors. This study however provides second level evidence for a protective effect 
of statins in late life depression for patients with a BMI >35.  
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Table 1 – Sociodemographic characteristics: Statin users vs Non-Statin Users 
 
 
 
       *Mean and Standard Deviation 
       ** Median and IQR 
 
 Number of Participants Statin User (%) Non-Statin User (%) P value 
Overall 19,114 5,987 (31.32) 13,127(68.68)  
Gender     
Male 
Female 
  8,331 (43.59) 
10,783 (56.41) 
2,337 (39.03) 
3,650 (60.97) 
5,994 (45,66) 
7,133 (54.34) 
<0.001 
Living Status     
At home alone 
At home with someone 
In a residential home 
  6,252 (32.71) 
12,779 (66.86) 
       83 (0.43) 
2,001 (33.42) 
3,959 (66.13) 
     27 (0.45) 
4,251 (32.38) 
8,820 (67.19) 
     56 (0.43) 
0.34 
Education     
<= 12 years 
> 12 years 
10,955 (57.32) 
  8,158 (42.68) 
3,668 (61.27) 
2,319 (38.73) 
7,287 (55.52) 
5,839 (44.48) 
<0.001 
Smoking History     
Current 
Former or Never 
     735 (3.85) 
18,379 (96.15) 
   238 (3.98) 
5,749 (96.02) 
     497 (3.79) 
12,630 (96.21) 
0.52 
Age     
65-70 
70-75 
75-80 
80-85 
> 85  
       564 (2.95) 
10,599 (55.45) 
  5,023 (26.28) 
  2,196 (11.49) 
      732 (3.83) 
   199 (3.32) 
3,306 (55.22) 
1,630 (27.23) 
   664 (11.09) 
   188 (3.14) 
   365 (2.78) 
7,293 (55.56) 
3,393 (25.85) 
1,532 (11.67) 
   544 (4.14) 
0.001 
 
Body Mass Index (BMI)     
<= 25 
25-30 
30-35 
> 35 
5,050 (26.53) 
8,452 (44.40) 
4,009 (21.06) 
1,524 (8.01) 
1,181 (19.83) 
2,670 (44.82) 
1,486 (24.95) 
   620 (10.41) 
3,869 (29.58) 
5,782 (44.21) 
2,523 (19.29) 
   904 (6.91) 
<0.001 
 
Blood Lipid Profile     
Total Cholesterol:  
<= 200 mg/dL 
>200 mg/dL 
 
LDL: 
<=100 mg/dL 
>100 mg/dL 
 
HDL: (<45 M, <55 F) 
Low  
High 
 
Triglycerides 
<=150 mg/dL 
>150 mg/dL  
 
9,090 (48.04) 
9,831 (51.96) 
 
   
5,604 (30.10) 
13,021 (69.90) 
 
   
  2,828 (15.15) 
15,842 (84.85) 
 
 
14,652 (77.06) 
  4,336 (22.94) 
 
4,407 (74.37) 
1,519 (25.63) 
 
 
3,488 (60.01) 
2,324 (39.99) 
 
 
1,056 (18.09) 
4,781 (81.91) 
 
 
4,232 (71.49) 
1,688 (28.51) 
 
4,683 (36.04) 
8,312 (63.96) 
 
   
2,116 (16.53) 
10,688 (83.47) 
 
   
  1,772 (13.81) 
11,061 (86.19) 
 
 
10,330 (79.6) 
  2,648 (20.4) 
<0.001 
Abdominal 
Circumference  
(<88cm F, <102cm M) 
    
Normal 
High 
  8,866 (46.86) 
10,055 (53.14) 
2,299 (38.74) 
3,636 (61.26) 
6,567 (50.57) 
6,419 (49.43) 
<0.001 
CES-D 10 scores     
< 8 
>= 8 
17,231 (90.17) 
  1,879 (9.83) 
5,351 (89.42) 
   633 (10.58) 
11,880 (90.51) 
   1,246 (9.49) 
0.019 
Antidepressant Use     
Yes 
No 
  2,145 (11.22) 
16,969 (88.78) 
   805 (13.45) 
5,182 (86.55) 
  1,340 (10.21) 
11,787 (89.79) 
<0.001 
Quality of Life (SF-12)     
Mental Component 
Score (MCS) 
Physical Component 
Score (PCS) 
55.7 (7.12) 
 
48.3 (8.76) 
55.56 (7.33) 
 
47.6 (8.94) 
55.71 (7.03) 
 
48.7 (8.66) 
<0.001 * 
Self-reported history of: 
Diabetes Mellitus  
High Blood Pressure  
 
1,709 (8.99) 
9,244 (75.68) 
 
1,082 (18.17) 
3,796 (85.15) 
 
   627 (4.80) 
5,448 (70.24) 
 
<0.001 
Number of Concomitant 
Medication 
3 (±4) 
 
4 (±3) 2 (±3)  <0.001 ** 
Table 2 – Examining association between statin use and depression (CES-D >8) 
 
 OR 95% Confidence Intervals P value 
Any statin  
Simvastatin  
1.13 
1.22 
1.02 – 1.25 
1.04 – 1.42 
0.02 
0.01 
Gender adjusted     
Statin 
Simvastatin 
1.09 
1.17 
0.99 – 1.21 
1.00 – 1.36 
0.08 
0.04 
Age and Gender adjusted    
Statin 
Simvastatin 
1.10 
1.17 
0.99 – 1.21 
1.00 – 1.37 
0.07 
0.04 
Multivariate analysis *    
Statin 
Simvastatin 
1.09 
1.16 
0.98 – 1.20 
0.99 – 1.35  
0.11 
0.05 
* Accounting for gender (OR: 1.6 for females), living status (At home alone: OR: 1.3 females, OR:2.0 males; In a residential home: OR 2.2 
females, OR: 2.7 males), education (OR: 1.2, <12 years) and smoking history (OR: 1.4 females, OR; 1.8 males, for current smokers) (all 
significant at .05 level). Non-significant variables were excluded from multivariable models using a backward elimination method. 
 
 
 
Table 3 – Subgroup analyses accounting for age, metabolic syndrome conditions and antidepressant use 
 
Subgroup analysis Total number of 
participants (%) 
                        CES-D =>8 MOR† 95% Confidence 
Intervals 
P value 
BMI  Statin: n (%) 
N=633 
Non-Statin: n 
(%) 
   
<= 25 
25-30 
30-35 
35+  
5,050 (26.53) 
8,452 (44.40) 
4,009 (21.06) 
1,524 (8.01) 
108 (9.15) 
278 (10.42) 
172 (11.57) 
  71 (11.45) 
355 (9.18) 
503 (8.70) 
243 (9.64) 
139 (15.38) 
0.95 
1.16 
1.20 
0.69 
0.75 – 1.19 
0.99 – 1.36 
0.97 – 1.48 
0.51 – 0.95 
0.63 
0.05 
0.08 
0.02 
Age      
<=74 
75-84 
85+ 
11,163 (58.40) 
 7,219 (37.77) 
    732 (3.83) 
351 (10.02)  
265 (11.56)  
   17 (9.04)   
726 (9.48) 
459 (9.32) 
 61 (11.21) 
1.02 
1.21 
0.82 
0.89 – 1.17 
1.04 – 1.43 
0.47 – 1.45 
0.75 
0.01 
0.51 
Diabetes       
Yes 
No 
1,709 (8.99) 
17,309 (91.01) 
145 (13.41) 
481 (9.88) 
   83 (13.24) 
1,161 (9.34) 
1.00 
1.01 
0.75 – 1.33 
0.91 – 1.13 
0.99 
0.78 
Hypertension       
Yes 
No 
9,244 (75.33) 
2,970 (24.66) 
414 (10.91) 
80 (12.08) 
556 (10.21) 
215 (9.32) 
1.05 
1.29 
0.92 - 1.21  
0.98 – 1.70 
0.45 
0.07 
Abdominal 
Circumference 
      
Normal 
High 
8,866 (46.86) 
10,055 (53.14) 
198 (8.62) 
424 (11.66) 
556 (8.47) 
678 (10.56) 
0.98 
1.08 
0.83 – 1.17 
0.95 – 1.23 
0.89 
0.22 
Antidepressant        
Yes 
No 
  2,145 (11.22) 
16.969 (88.78) 
   174 (27.49) 
   459 (72.51) 
282 (22.63) 
964 (77.37) 
1.01 
1.06 
0.82 – 1.26 
0.94 – 1.19 
0.88 
0.32 
* Accounting for gender, living status, education and smoking history (all significant at .05 level). Non-significant variables were excluded 
from multivariable models using a backward elimination method. † MOR: model-adjusted odds ratio 
 
  
 
 
  
 
 
